Risultati della ricerca - Brendon L. Neuen

Raffina i risultati
  1. 1
    Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities

    Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities di Kris Vijay, Brendon L. Neuen, Edgar V. Lerma

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Empagliflozin in Patients with Chronic Kidney Disease

    Empagliflozin in Patients with Chronic Kidney Disease di Brendon L. Neuen, Robert A. Fletcher, Hiddo J.L. Heerspink

    Pubblicazione 2023
    Testo
    Carta
    Aggiungi alla lista
    Salvato in:
  3. 3
    Chronic kidney disease and the global NCDs agenda

    Chronic kidney disease and the global NCDs agenda di Brendon L. Neuen, Steven J. Chadban, Alessandro Demaio, David W. Johnson, Vlado Perkovic

    Pubblicazione 2017
    Testo Testo
    Editorial
    Aggiungi alla lista
    Salvato in:
  4. 4
    Chronic kidney disease

    Chronic kidney disease di Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic

    Pubblicazione 2021
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials

    Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials di Edward W. Webster, Adam Perkovic, Brendon L. Neuen, Katherine R. Tuttle, Vlado Perkovic

    Pubblicazione 2025
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review

    Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review di Brendon L. Neuen, Ronny Gunnarsson, Angela C Webster, Richard Baer, Jonathan Golledge, Murty L. Mantha

    Pubblicazione 2014
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients

    Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients di Brendon L. Neuen, Nicole Leather, A.M. Greenwood, Ronny Gunnarsson, Yeoungjee Cho, Murty L. Mantha

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

    SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review di Merlin C. Thomas, Brendon L. Neuen, Stephen M. Twigg, Mark E. Cooper, Sunil V. Badve

    Pubblicazione 2023
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  9. 9
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes di Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis... di Tadashi Toyama, Brendon L. Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg Jardine, Hiddo J.L. Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada, Vlado Perkovic

    Pubblicazione 2019
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

    Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials di Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang

    Pubblicazione 2024
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

    Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis di Clare Arnott, Qiang Li, Amy Kang, Brendon L. Neuen, Séverine Bompoint, Carolyn S.P. Lam, Anthony Rodgers, Kenneth W. Mahaffey, Christopher P. Cannon, Vlado Perkovic, Meg Jardine, Bruce Neal

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  13. 13
    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial

    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial di Jennifer Barraclough, Jie Yu, Gemma A. Figtree, Vlado Perkovic, Hiddo J.L. Heerspink, Brendon L. Neuen, Christopher P. Cannon, Kenneth W. Mahaffey, Aletta E. Schutte, Bruce Neal, Clare Arnott

    Pubblicazione 2022
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... di Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol A. Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

    Pubblicazione 2023
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program di Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh, Hiddo J.L. Heerspink, Vlado Perkovic

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program di Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Jaime D. Blais, Qiang Li, Meg Jardine, Vlado Perkovic, David C. Wheeler

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS di Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis di Brendon L. Neuen, Robert A. Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V. Badve, Katherine R. Tuttle, Richard E. Pratley, Hertzel C. Gerstein, Vlado Perkovic, Hiddo J.L. Heerspink

    Pubblicazione 2024
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  19. 19
    The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial

    The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial di Clare Arnott, Yuli Huang, Brendon L. Neuen, Gian Luca Di Tanna, Christopher P. Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Bruce Neal

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis di Brendon L. Neuen, T. Kue Young, Hiddo J.L. Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W. Mahaffey, David M. Charytan, David C. Wheeler, Clare Arnott, Séverine Bompoint, Adeera Levin, Meg Jardine

    Pubblicazione 2019
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: